Indeed, a large study of 1576 patients with invasive breast cancer demonstrated that COX-2 was expressed at high levels in over 50% of patients and these patients had a significantly worse disease-free survival compared with patients whose tumours expressed low-levels of, or absent, COX-2 (Ristimaki et al, 2002). Here, PTGS2 is linked to invasive breast carcinoma.